LunarCrush LLM | creator/twitter::955983797543161857/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@BIOTECHBATMAN](/creator/twitter/BIOTECHBATMAN)
"$ions truly firing on all cylinders. They should rapidly move towards $alny valuation as their pipeline increasingly moves to approved drugs with tech development (tissue spec ligands ultra long half-life modifications) that will make it challenging for any competitor to match"  
[X Link](https://x.com/BIOTECHBATMAN/status/1965398924396822614) [@BIOTECHBATMAN](/creator/x/BIOTECHBATMAN) 2025-09-09T12:56Z XXX followers, XXX engagements


"Ioniss first siRNA clinical trial well underway and already has positive data. Target is apoC-III for biannual dosing. This seems strategic designed to kill any advantage a competitor may have taking the fast follower strategy. $ions $alny $arwr"  
[X Link](https://x.com/BIOTECHBATMAN/status/1975547425038422076) [@BIOTECHBATMAN](/creator/x/BIOTECHBATMAN) 2025-10-07T13:03Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BIOTECHBATMAN "$ions truly firing on all cylinders. They should rapidly move towards $alny valuation as their pipeline increasingly moves to approved drugs with tech development (tissue spec ligands ultra long half-life modifications) that will make it challenging for any competitor to match"
X Link @BIOTECHBATMAN 2025-09-09T12:56Z XXX followers, XXX engagements

"Ioniss first siRNA clinical trial well underway and already has positive data. Target is apoC-III for biannual dosing. This seems strategic designed to kill any advantage a competitor may have taking the fast follower strategy. $ions $alny $arwr"
X Link @BIOTECHBATMAN 2025-10-07T13:03Z XXX followers, XXX engagements